Thanks and good morning. Thanks for joining us for our fiscal fourth quarter 2019 earnings conference call.

Joining me today are John Groetelaars, President and Chief Executive Officer of Hill-Rom; and Barbara Bodem, Chief Financial Officer.Before we get started, let me begin our prepared remarks by reminding you that certain statements contained in this presentation are forward-looking statements and are subject to risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those described. Please refer to today’s press release and our SEC filings for more detail concerning risk factors that could cause actual results to differ materially.In addition, on today’s call, non-GAAP financial measures will be used.

Reconciliations between GAAP and non-GAAP financial measures are included in our earnings release issued this morning.As you know, beginning with our fiscal first quarter, we adopted the new revenue recognition accounting standard ASC 606 on a modified retrospective basis. The focus of our commentary this morning will be on our financial results under this new standard for the current and prior-year periods, which will allow for comparability on an apples-to-apples basis as well as comparisons to our 2019 financial guidance.This morning we have a lot of ground to cover.

We’ll be discussing our fourth quarter and full year 2019 financial results and our 2020 guidance. We will then switch gears and highlight our new 3-year financial outlook through fiscal 2022 before opening up the call for Q&A.We’ve included additional details in a comprehensive presentation that can be accessed on the Investor Relations page of our website at www.hillrom.com, under Events and Presentations.So with that introduction, let me now turn the call over to John.

Thanks, Mary Kay. Good morning, everybody.

Let me start by saying 2019 was a very successful year for Hill-Rom. We concluded our fiscal year with strong broad-based momentum across the portfolio in both the U.S.

and international.In Q4, we achieved 8% core revenue growth and 11% adjusted EPS growth, excluding stock-based comp in both periods. Once again, these financial results exceeded expectations.

For fiscal 2019, adjusted earnings of $5.08 per diluted share reflects the 6th consecutive quarter of core revenue growth in mid-single-digits or higher.New product revenue was more than $450 million and adjusted operating margin was 17.8%. Margin expansion was driven by multiple factors.

These include favorable mix from new products, accretive M&A, portfolio optimization efforts, efficiencies from our manufacturing operations team and SG&A leverage.Importantly, disciplined execution more than offset tariffs, near-term dilution related to surgical consumables divestiture and discreet onetime costs in fourth quarter.We are also investing back into business to bolster durable top-line growth over the long term. The Hill-Rom team has delivered each and every quarter this year, consistently achieving financial results above expectations on both the top and bottom line, and setting a solid foundation for the future success in 2020 and beyond.Our category leadership strategy and four strategic priorities continue to deliver significant value to patients, caregivers and shareholders.

I couldn’t be more pleased with the execution of our team to deliver impressive core revenue growth of 8% in Q4 and 7% for the full year. Contribution from acquisitions accelerated in Q4, by adding more than 150 basis points to growth and 80 basis points for the full year.One of the most exciting highlights was the impact of new product innovation on our top-line.

We delivered more than $450 million in new product revenue for 2019 compared to $300 million last year, exceeding our 2020 objective one year early and maturely above our goal. While some revenue is cannibalizing, the incremental contribution from new products was about 300 basis points for the year.Performance overall is being driven by 8 key products across all 3 businesses.

New products launched in 2019 include RetinaVue 700 Imager, EarlySense and WatchCare. With several additional new products in the pipeline, we expect durable growth from new products to continue well into the future.Performance in Q4 was balanced geographically.

U.S. growth was 9%, both Patient Support Systems and Surgical Solutions grew in double-digits.

And this more than offset anticipated difficult comps in Front Line Care, primarily due to the pent up demand as we launched the Monarch vest in the U.S. last year.International growth of 7% is the highest level achieved in 7 quarters and it was powered by performance across all 3 businesses: in Asia Pacific, Latin America and EMEA.Now, let me take a moment to review the performance by business at constant currency rates.

First, Patient Support Systems revenue grew 11% in Q4, while core revenue advanced 14%. This is the highest rate of the year despite a very challenging comp in Centrella last year.Excluding Voalte, the business grew 11%, driven by positive contributions from across the broad portfolio of Connected Care solutions and services, including care communications and smart beds.This momentum continues to reflect the stable capital spending environment, where the current mix is favorable to our portfolio.

We currently see no signs of this trend changing. Our detailed analysis of historical hospital capital spending highlights a stable and growing environment since the financial crisis ended in 2009.Historically, the U.S.

med-surg category has been the most sensitive segment, vulnerable to capital spending shifts. And today, our portfolio is much more diverse and resilient than it was in the past.

This category only represents 10% or less of our total revenue.For the year, Patient Support Systems’ core revenue growth was 10%, reflecting a strong market response from customers as they embraced Hill-Rom’s Connected Care solutions. With a continuum from smart bed to smart phone, we are simplifying communications, improving workflows and delivering better outcomes across healthcare.With more than $1 million devices that can be connected at the point of care, and future digital product opportunities, Hill-Rom has created a significantly differentiated offering that provides valuable real-time clinical data and insights that will drive value by improving workflow, safety and equality.

Q4 Front Line Care revenue declined 1%. As expected, the prior year U.S.

growth rate of 8% made for a challenging comparison.Excluding this impact Front Line Care revenue increased 3%. Contributors to growth came from international growing at 7%, along with respiratory health products, thermometry and the vision portfolio.For the year, Front Line Care grew 3%.

Lastly, Surgical Solutions’ Q4 revenue declined 6% reflecting the divestiture of surgical consumables. Core revenue however advanced 11% with double-digit growth in patient positioning and select OR equipment, and a record number of quarterly placements of the Integrated Table Motion for the da Vinci robot.For the full year, surgical core revenue growth was 5%.

As you know, in 2019, we continue to successfully reshape our portfolio through strategic growth-oriented acquisitions and select divestitures of low-growth businesses.Since 2016, we’ve divested more than $300 million of annualized non-core, non-strategic revenue. While this has muted reported revenue growth, our fourth quarter results are an encouraging indication that our focus on innovation along with these strategic portfolio moves are contributing to top-line acceleration.As we’ve mentioned, 2020 is the last fiscal year with non-core revenue.

The acquisition of Breathe Technologies and Voalte represent excellent examples of how we plan to strategically deploy capital to advance category leadership in higher growth, higher margin categories while adhering to our rigorous strategic and financial criteria to generate attractive returns.It’s still early days, but Voalte integration has remained on track. Voalte in particular continues to exceed expectations with strong revenue growth.

We are also beginning to uncover commercial synergies as we expand our care communications market leadership and drive incremental value over the long range outlook.And with the Breathe Life2000 Ventilator, we are looking forward to leveraging our vertically integrated direct commercial model in a new attractive market, with this disruptive non-invasive respiratory therapy for patients in both the acute care and home settings.Lastly, the divestiture of surgical consumables underscores our decision to exit a business that was a headwind to our growth aspirations and strengthens our ability to focus resources and capital towards the future Hill-Rom. Since the divestiture does not qualified for treatment as discontinued operations, we are absorbing the related earnings dilution in our fiscal 2020 financial guidance.

Excluding the divestiture in the base year, we expect to deliver 11% to 13% adjusted earnings per diluted share in fiscal 2020.In summary, we are exiting 2019 from a position of strength and momentum. We are energized by a progress and look forward to 2020 and beyond another chapter in our transformational journey.

Today, we are unveiling a compelling 2020 and 3-year financial outlook, a multiyear plan of durable mid-single-digit revenue growth, double-digit earnings growth and strong cash flow. This plan includes the benefit of new product momentum, emerging market penetration and value creation from recent M&A.We also included transformational investments in our IT infrastructure and commercial capabilities to sustain long-term top-line growth and enhanced profitability.

We look forward to providing additional details later in the call today.Finally, as I reflect on my first year as CEO, I am extremely proud of our progress and what we have accomplished. I want to personally acknowledge the global team at Hill-Rom for their unwavering commitment to our mission and for their winning spirit.

At Hill-Rom, our passion continues to be on enhancing outcomes for patients and caregivers providing connected and advanced solutions that add significant value to the delivery of healthcare across all care settings from the hospital to the surgical suite to the physician’s office and at home. As we look for the future, we will continue to build on this solid foundation in pursuit of our vision of Advancing Connected Care.Thanks.

And let me now turn the call over to Barb.

Thanks, John, and good morning, everyone. Our commentary this morning will focus on fourth quarter results on a comparable basis to the prior year period adjusted for ASC 606.

Please use the supplemental schedules posted to our website to follow along.For the fiscal fourth quarter, under revenue accounting standard ASC 606, we reported GAAP earnings of $0.41 per diluted share. These results include after-tax special items related to intangible amortization, acquisition and integration costs, and other special charges.

Adjusted earnings of $1.69 per diluted share exceeded our guidance range of $1.64 to $1.66 per diluted share.I will now review the quarter by P&L line item. Starting with revenue, for the fiscal fourth quarter, reported revenue of $783 million increased 3%, 4% on a constant currency basis.

Core revenue advanced 8% exceeding our guidance range of approximately 5% core growth. Acquisitions contributed more than 150 basis points, so excluding acquisitions core growth was 6%.Adjusted gross margin of 49.9% expanded 30 basis points over the prior year, driven by execution across all 3 businesses with tremendous support from our global operations team.

Gross margin expansion continues to benefit from positive product mix, including the impact of new products, accretive M&A as well as operational improvement. Collectively, operational performance provided flexibility to once again absorb tariffs and raw material inflation and offset discrete one-time costs of approximately $4 million or $0.05 per diluted share.

Excluding these one-time costs, gross margin expanded 80 basis points for the quarter and for the year in line with our expectations.R&D spending for the quarter was $36 million, reflecting our ongoing commitment to innovation and investments in key programs to drive future growth. Adjusted SG&A of $191 million increased 3% due to strategic investments primarily in emerging markets as well as the impact of recent acquisitions.Our adjusted operating margin in the fourth quarter was 20.9% reflecting an improvement of 30 basis points compared to the prior year.

Excluding the one-time costs mentioned earlier, operating margin expanded 80 basis points for the quarter and 100 basis points for the year. The adjusted tax rate was 19.5%.

Stock-based compensation was a benefit of $0.04 per diluted share in the quarter, presenting a significant headwind when compared to the $0.15 benefit last year. So bottom line, adjusted earnings for the fourth quarter increased 3% to $1.69 per diluted share.

Excluding stock-based compensation, earnings per share increased 11%.Now turning to cash flow, cash flow from operations for the year was $401 million. Capital expenditures totaled $73 million.

And as a result, we generated free cash flow of $328 million, which is 7% higher than last year. In terms of the balance sheet and financial leverage, our debt-to-EBITDA ratio at the end of September was 3.2 times, and we’ve returned $177 million to shareholders through dividends and share repurchases during the 2019 fiscal year.Let me conclude this portion of the call with our guidance for fiscal 2020.

First, for the full year, we expect revenue growth of 1% to 2% both on a reported and constant currency basis. Core revenue is expected to be in the 5% to 6% range.

Excluding the incremental benefit from acquisitions, core revenue growth is expected to be in the 4% to 5% range.Non-core revenue totaled $150 million in 2019 and is expected to total approximately $25 million in 2020. The vast majority of the year-over-year decline is attributed to the completion of the 2019 surgical consumable divestiture.

The reminder relates to the pending exit of the international surgical OEM products, which we plan to complete before the end of 2020. As we have mentioned 2020 is the last year, we will report non-core revenue as core and constant currency growth rate begin to converge in 2021.From a profitability standpoint, we expect adjusted gross margin to expand 100 and 150 basis points.

We expect R&D to increase in the low-single-digits representing approximately 5% of sales. We expect adjusted SG&A of approximately 27.5% of sales.

This reflects the impact of recent M&A transactions, investment in key growth initiatives as well as business optimization savings.Our guidance also includes a step-up investment related to a global IT transformation, including an enterprise resource planning effort to consolidate and streamline our IT systems. This multiyear investment will modernize and transform the way we do business, improved customer service and our customer’s experience as well as drive future operating efficiencies and incremental savings by year 3 of our new financial outlook.

As a result of solid gross margin expansion and strategic investments, we expect an adjusted operating margin of approximately 18.5%. With savings from our recent debt refinancing, we expect other expense, which includes interest of $75 million to $80 million.And lastly, we expect a tax rate of approximately 20% and a share count of 67.7 million shares.

This translates into an adjusted earnings guidance range of $5.46 to $5.56 per diluted share. On a reported basis, adjusted earnings per share growth is expected to be in the 7% to 9% range, when excluding the impact of the surgical consumable divestiture, adjusted earnings per share growth is expected to be in the 11% to 13% range.From a cash flow perspective, we expect operating cash flow of approximately $430 million, including the impact of transaction related outflows and capital expenditures of approximately $100 million, which includes the first year of our IT investment.

This translates into free cash flow guidance of approximately $330 million.For the fiscal first quarter, we expect revenue to be comparable to the prior year period on both a reported and constant currency basis. Core revenue is expected to increase 5% to 6%.

Excluding acquisitions, we expect core revenue growth of approximately 4%. We expect adjusted earnings, excluding special items of $1.07 to $1.09 per diluted share.Thanks.

And now, I’ll turn the call back over to John.

Thanks, Barb. At this point, I’d like to turn to our 3-year outlook through 2022.

As a reminder, details are also available in our earnings presentation posted to our website. For those of you that have followed Hill-Rom, that we have significantly diversified our business, enhanced our value propositions and improved our durable growth profile through deployment of both organic and inorganic investments, leading to an exciting and compelling transformation.

In fact this year, you had seen an updated brand for the company reflecting these changes.We’ve established a strong track record of performance that has consistently met or exceeded expectations, and we’re entering 2020 with solid momentum and high confidence. Our objective today is to share with you, how we plan to sustain this elevated level of performance as we execute our plans.

With a solid 2019 foundation, clear strategy and seasoned leadership team, we will continue to drive enhanced value by executing on our 4 strategic priorities.First, let me start with category leadership to accelerate top-line growth with innovative new products and solutions. We continue to focus on high value, high growth and high margin categories, where organic R&D efforts can drive market – can drive growth above the market.

With a solid base of more than $450 million in new product revenue in 2019, we expect to launch 5 to 6 new products each year through 2022. New product launches will result in the contribution of approximately 200 basis points of growth annually over the 3-year plan.Our second objective is international expansion and driving penetration in emerging markets.

Enhancing access to care in emerging markets is a source of untapped potential for Hill-Rom, this is not – this not only represents a significant growth opportunity, it will be a key driver of reducing quarterly variability across our total international business. Today, international represents approximately 30% of our global revenue and emerging markets represents only 9% of our global revenue.As the emerging markets provide increased access to quality healthcare, patients will benefit from our company’s unique and competitive offering and select product areas, and recent investments will further strengthen Hill-Rom’s competitiveness.

As mentioned, we are in the early stages of reinvigorating our commercial operations in these markets with new leadership, organizational capabilities and a focus on key strategic products. We expect meaningful growth acceleration over this period.Over the next 3 years, emerging market growth is expected to increase to high-single-digits in 2020 and ramp-up the double-digits thereafter, adding approximately 100 basis points of top-line growth annually over this 3-year period.Third, M&A, it’s a key component to our strategy and we have made great progress and strengthening our portfolio.

The recent acquisitions of Voalte and Breathe created durable new source of growth over a multiyear period. Additional M&A opportunities exist to drive accretive revenue and enhanced margin profile, while strengthening our clinical and economic value proposition to our customers.We will continue to be prudent in the evaluation of these opportunities, adhering to our rigorous strategic and financial criteria to generate attractive returns.

We expect future M&A to be incremental to the 3-year plan we are outlining today.Lastly, we are committed to driving operational execution and strong financial performance. Our 3-year outlook includes a core revenue growth of approximately 5%, double-digit earnings growth and significant cash flow generation.

The P&L profile reflects a commitment to driving value by continuing to stay focused on both organic and inorganic investments that are already completed to accelerate top-line growth, while improving our operating margin profile. Given our confidence, we elected to take a multiyear investment to transform our IT information systems, including an enterprise resource planning initiative.And while this is expected to be modestly dilutive to operating margin in the near-term, we believe that the time is right now to execute on this decision and position us for future growth and success.

So with this as a backdrop today, we are providing details on our financial outlook through 2022.Let me turn the call back over to Barb, and hopefully, her voice can hang in there through the rest of this call before we open the call up for Q&A.

Thanks, John. It is my pleasure to present details regarding Hill-Rom’s financial outlook through 2022.

We have a compelling vision and want to ensure that you have a clear understanding of how it is expected to manifest itself in the financial performance of Hill-Rom over the next several years. Before we get into the details, let me take a moment to review the key assumptions included in our projections.First, we assume no major changes to the global macro environment.

We are assuming persistent competitive conditions and modest price pressures in select areas of the portfolio. We also assume a stable hospital capital spending environment in the United States.As we discussed, reported revenue incorporates a headwind related to the non-strategic assets we have exited, including the surgical consumables divestiture in 2019 and the expected exit of the international surgical OEM products in 2020.This non-core revenue totals approximately $150 million in 2019 and $25 million in 2020.

This outlook assumes the permanent repeal of the medical device excise tax, constant foreign change rates, and excludes unusual nonrecurring items and special charges. We are not including any benefits from future M&A nor any incremental impact from additional tariffs, or potential healthcare, government or tax reform.Now, given these assumptions, let me describe the 2022 financial objectives.

With fiscal 2019 serving as the base year, we expect core revenue to grow at a rate of approximately 5% on a compound annual basis through 2022.This growth is inclusive of recent acquisitions, as these acquisitions anniversary early in the outlook and their incremental 2020 benefits is negligible to the 3-year revenue compound annual growth rate.As mentioned, we expect the non-strategic revenue of approximately $150 million in 2019 to be a headwind to the reported top-line compound annual growth rate by approximately 100 basis points. Therefore, reported revenue is expected to grow approximately 4% on a compound annual basis at current foreign exchange rates.Core growth and constant currency growth begin to converge in 2021.

In addition, we expect very balanced core growth across the 3 businesses, each growing in mid-single-digits on a constant currency basis over the planning period.We expect our reported adjusted earnings per diluted share to grow at least 10% on a compound annual basis from 2019 through 2022. Excluding the surgical consumables in the base year of 2019, we expect adjusted earnings per diluted share to increase at least 12% compounded over the 3-year period.Our accelerated growth and performance is expected to drive significant cash flow, and we expect to generate approximately $1.4 billion in cumulative operating cash flow between 2020 and 2022, with capital expenditures totaling approximately $325 million over this timeframe.Consistent with our strategic objectives, we will continue to deploy a very disciplined approach to capital allocation.

As we identify value-creating opportunities, we will not be reluctant to deploy capital and resources towards organic or inorganic initiatives to fuel accelerated profitable growth.In the absence of these opportunities, deleveraging the balance sheet will be our top near-term priority. In summary, our outlook reconfirms our commitment to durable mid-single-digit top-line growth and continued double-digit bottom-line growth.Now, for the purposes of financial modeling, we are providing our view as of today on the other P&L line items.

As you know, due to a wide variety of factors which could materialize over the next 3 years, the shape of the P&L may evolve over time, as we manage to our top- and bottom-line commitments.On the margin front, we expect at least 250 basis points of growth margin expansion, achieving the 2022 adjusted gross margin of approximately 52% compared to 49.5% in 2019. Our model shows adjusted operating margin to expand by approximately 300 basis points to approximately 21% by 2022 from 17.8% in 2019.Gross margin expansion is expected to be driven by new product and geographic mix, the accretive benefit from recently completed acquisitions and improved manufacturing cost and productivity.In recent years Hill-Rom has demonstrated an ability to drive strong operating performance while being diligent in managing G&A and driving efficiency across the business.

As we continue to focus on driving durable sustainable top-line growth, our 2022 plan includes investment in key initiative to support this future growth.As a result, we expect SG&A as a percentage of revenue to be approximately 26.5% in 2022 and R&D spending to be approximately 5% of revenue annually.We have executed well across our business optimization initiatives and are pleased to have already achieved approximately 2/3 of our estimated $50 million in pre-tax savings over the last few years.As you know, these savings are intended to be reinvested to allowing resources with key priority growth areas, expand internationally and optimize global capabilities across the business.We are projecting annual interest expense of $75 million to $80 million, including benefits from our recent debt refinancing and underlying tax rate for Hill-Rom of approximately 20% over the period. We are also assuming a stable share count of approximately 67.7 million shares.In summary, we believe this to be a very balanced plan with consistent, durable and sustainable mid-single-digits top-line growth and double-digit adjusted EPS growth in each year including 2020 when excluding the impact of the surgical consumable divestiture.We look forward to updating you quarterly on our execution.

Thanks. And I’ll turn the call back over to John.

All right, let me wrap up our prepared comments this morning and summarize that our transformation continues. We are capitalizing on the strength of our core business, focused on accelerating durable and profitable revenue growth and generating strong earnings and cash flow over the next 3 years.New product momentum continues to build.

We are advancing our pipeline and penetrating emerging markets. And we continue to pursue M&A transactions that are accretive to our growth and margin profile, while generating attractive returns.We have a solid foundation and a great team.

With a compelling strategy, disciplined operational execution and financial strength, we are excited about our future and driving value for patients, customers and our shareholders.So, operator, with that, we’ll turn over the call for Q&A.

Hi, thank you for taking the question. So I wanted to ask a little bit about fiscal 2020 first.

And you drove a lot of new product revenue here in fiscal 2019. Could you talk about your confidence in being able to continue getting that kind of 200 to 300 basis points contribution from new product revenue in 2020 and what are the major drivers of that?

Yeah, thanks, Matt. We have a lot of great confidence actually in our product pipeline.

We expect to be launching, as mentioned in the prepared comments, 5 to 6 new products per year over the 3-year period. But in fiscal 2020, a little more specifically it’s actually more than 6 products – 6 significant product launches that will take place in 2020.

They come across all three of our businesses, both – all 3 equally, PSS, Front Line Care and our surgical business.So those products we haven’t, for competitive reasons, kind of disclosed the specifics of them. But we feel really good about, that the products that are coming in the marketplace and really would help offset some of the Centrella performance that we saw this year.As mentioned in prior meetings, we do expect the Centrella double-digit growth rate in fiscal 2019 to come down to more like a low-single to mid-single-digit growth rate in fiscal 2020.

So taking that into account, we feel really good about our 200 basis points of incremental growth that we expect from the new product portfolio in total, with the biggest adjustment there on having a very prudent outlook for the Centrella performance in fiscal 2020 off of some really high-double-digit performance in fiscal 2019.

Got you. Thanks, John.

And then, it sounds like the Voalte and the Breathe acquisitions are doing well and integrating well. Can you talk a little bit more of the outlook for those?

What kind of sustainable growth can you drive with those deals and maybe talk about peak sales or some kind of other measure for us to understand what the longer-term opportunity is there?

Yeah, I’ll take this question. In Q4, Breathe really was immaterial to comp.

It only had 1 month in the quarter, so it wasn’t even on the measurability scale in Q4. So, all that acquisition growth in Q4 was coming from Voalte, which you would see sequentially growing from Q3 to Q4, which we love.

That was our intention when we’re acquiring the business that would fit very nicely with our care communications portfolio. And we would begin to accelerate the order and revenue performance of that asset and that business.And that’s exactly what is done.

In fact, it’s beating our expectations. So we’re really pleased with how that’s performing.

It’s two more quarters ahead of us before that annualizes and roles into the base organic growth rate. So we’re pleased with that.On the Breathe front, it’s early days, but the integration is going really well.

We just had a big meeting with the combined team a few weeks ago. They are really excited to have this portfolio come together and come to market with a full respiratory health portfolio that now includes a new disease state of COPD.And that as you know, and we talked about it before, the non-invasive ventilation category is a high-double-digit grower and it’s a large market.

And it’s a market for us that is all upside, because we’ve never had a product offering in this category for us. So for us to come in with a very substantial sales organization that it combines with Breathe and a vertically integrated DME to capture all the value in this opportunity, we’re quite bullish on the long-term prospects of building out a respiratory health business for the disease state of COPD and other related diseases, but COPD is the biggest one.So pretty excited about those two and off to a great start, Matt.

Thanks for the question.

Thanks, John.

Great. Just a couple for me, John, just real quickly on emerging markets, so just kind of LRP versus 2020, the LRP sort of calling for double-digit EM growth kind of through the plan, which makes perfect sense.

In 2020, is that a realistic expectation for the emerging markets business?

We’re projecting, David, high-single-digit on emerging markets. We aspire to do better, of course.

But we exited the year in Q4 with our emerging markets growing at 8%. So we’re exiting 2019 in the right position to sustain that performance.

That’s what baked into our guidance for fiscal 2020.And like I say, we like the way things are tracking with our investments in emerging markets. We would aspire to do better, but what’s baked into guidance is a high-single-digit number for emerging markets and a low-single-digit growth number for established markets, which is probably given historical performance over a multi-year period a much more prudent and, I guess, balanced outlook between the two markets: emerging and established.

Okay. And just so, two more quick ones for me, first just on – I mean, the real difference in fiscal 2020, since you’re at the 5 to 6 guide versus us, it does appear I think it’s Voalte and Breathe.

For Voalte and Breathe, total revenue contribution for next year is a – the number in excess of $70 million, a decent way of thinking about those 2 contributions, and are there any sort of back-half loaded dynamics to Breathe for us to consider? That’s for you, John.And then for Barbara, I just wondered sort of high-level, you think about fiscal 2022, the long-term LRP, there are some differences in terms of kind of gross margin expansion, operating margin expansion.

I’m just wondering if you could talk about how the next 3-year outlook vary for the prior 3-year outlook as it relates to mix-driven benefits on gross margin and the opportunity of – for middle of the income statement leverage? Thanks so much.

Yeah, so, on the acquisition outlook we would expect acceleration in the back-half of the year with the Breathe acquisition. We really are acquiring a product that was in its very beginning of a product launch.

So, yeah, although it had a base of revenue when we acquired the company of around $10 million, it’s almost more realistic to think of it from the starting – from the starting line together.So we expect as we bring the two organizations together and build our sales proficiency that that will ramp towards the back-half of the year and become a contributor of around 50 to 100 basis points in the back half of the year on Breathe. And as I mentioned earlier, Voalte is going to anniversary midyear.

We like the way it’s performing at this point.So in total, you take it altogether, it’s about a full 100 basis points, maybe a little more of contribution from acquisitions over the full course of the year, maybe 150 basis points when you average it two together. So hope that answers your question, David, and I’ll pass it over to Barb.

Hi, David, how are you? So your question I think was around how is gross margin and operating margin evolving and the new 3-year outlook versus the prior year 3-year outlook.

I think in aggregate, the improvement that we’re seeing is very similar in terms of where we’re seeing what the improvement looks – it should look like over the next few years.When you think about gross margin, I think the way that I would look at gross margin in the mix there, is we’ve seen over the past couple of years the drivers of gross margin expansion to really be about the product mix. It’s been about the businesses we’ve been exiting as well as the new products we’ve been launching, as well as then the acquisitions that we’re bringing in that are also accretive to gross margin.

But the emphasis probably in the early part of the 3-year – the old 3-year plan really was probably getting a lift more from the divestitures and less from the new product portfolio moving it forward. We’ve also seen a great contribution from productivity over the past couple of years.And going forward, we will continue to see product mix be a big piece of where we’re going to see the expansion as well as productivity.

But when you think about the product mix, I would really be shifting away from the impact of the divestitures and more about the impact of the new product portfolio, and the new product portfolio being of higher gross margins as well as the ramping up of the recent acquisitions that our higher gross margin and their overall contribution over the next couple of years. So that would be how I would characterize the difference in the gross margin expansion over the past versus the future in what’s driving that.

David, it’s Mary Kay. I just would add to what Barb said, in terms of we look over the 2022 outlook and the margin – gross margin expansion in particular.

We think about just over half it’s going to come from the new products and mix and M&A, and a little bit less than half will come from the productivity improvements that Barb mentioned.

Okay. Very helpful.

Thank you. Sorry…

In regards to – I’m sorry. Did you want to – the second part of the question was around operating margin and just a couple of quick comments on operating margin as we think about the next 3 years.

We are still projecting significant expansion on operating margin 300 basis points over the next 3 years. What you’ll see, though, as you’ll see some investment on the frontend related to IT in particular, and then you are going to see the acceleration of our operating margin expansion in the latter part of the 3-year period as the impact of the IT investment starts to flow through as well as when we see really the greater contribution from the new acquisitions coming through and adding to the operating margin expansion in the latter part of the 3-year plan.

I think with that, we’re ready for the next question.

Thanks. Good morning, everyone.

2 questions, maybe just starting off for John. Just on the emerging markets and your thoughts through the 3-year LRP.

Is this really a China strategy or do you see it broader? And is there any way that you can sort of help us think about, how you’re thinking about margins for that emerging markets franchise?

Is it above the corporate average? Just trying to think about the profitability as you dig in here with the next 2 years on that?

Sure. Yeah, thanks for the question, Larry.

It’s broader than just China. It is an overall emerging markets strategy.

However, China is the biggest opportunity and most material opportunity within that group of geographies. So our definition of emerging markets would be very typical across the sector.

We would include LatAm and the Middle East and all of Asia – all of emerging Asia in that definition as well. So when you look at all that, the biggest opportunity for us is in China.From a margin point of view, it’s actually accretive to the overall corporate margin in total.

So we’re in the early phases here. As we invest, it’s slightly below the corporate level.

But as we mature those investments, we would expect it to be above our corporate margin levels.

Okay. Perfect.

And then for Barb, just on the IT platform, I know, you’ve mentioned it a couple of times here, but I guess a couple of questions. Is the right way to think about the step-up in the CapEx in 2020 mostly associated with that ERP system?

And how do you think about the total investment into the system? And on the other side, how are you thinking about the benefits both just sort of tactically as well as or strategically as well as just financially, savings from getting this ERP system in place?

That’s a great question. Thanks very much for it.

First of all, we believe that the transformation that we’re heading into with IT is a key enabler, a key long-term enabler for all 4 of our strategic priorities. So the investments supposed to take place over the next 3 to 4 years, it’s intended to modernize and transform the way we do our business really improving our customers service and their experience with us.

But it will also be driving future operating efficiencies and incremental savings.The total investment that we’re looking at over the next 3 or 4 years, we’re estimating to be about $100 million, and that’s going to be a mix of CapEx and operating expenses. You are correct that the step-up in CapEx that we’re seeing in 2020 is directly correlated with the increased investment we’re anticipating in the IT.

And then the longer-term, as we get the transformation moving, we expect to see somewhere between in 20 and 40 basis points expansion and operating margins related to the efficiencies that we get out of this investment.

Okay. Perfect.

Thanks, guys. I appreciate it.

Okay. Great.

Thanks. Good morning.

Just a couple of quick follow-ups. Probably just a follow-up on that last one, on the IT transformation, what’s the magnitude of the cost running through the P&L, say, in 2020 and 2021?

As we look at 2020, we’re estimating approximately $10 million of operating expense related to the IT transformation. It will – we’re still working through our planning, so to say precisely what 2021 will look like is hard to say.

It will probably in the neighborhood maybe a couple of million dollars less. But we’ll update that as we get closer to 2021.

Okay. And then just 2 more quick ones.

Thank you for that. On the Voalte side, just curious – in the quarter, just curious as to what the pro forma growth rate was of Voalte in the fourth quarter.

Rough estimates look like it might have been approaching 20%, but just curious to see, how it did in the quarter on a pro forma basis?

Yeah, it’s probably a little bit above that number you quoted there, Bob. It’s high double-digit on an apples-to-apples basis as we look at it.

We’re really pleased with the performance of the product. We love the way we’re competing in the marketplace and the response we’re getting from customers around the combination of Voalte plus the Hill-Rom portfolio has been really well received.

As an interesting side note, the care-com business now, while we’ve been talking all about Centrella all year long, the care-com business has actually been growing at double-digits, and it’s actually in total larger than the med-surg business in total. So care-com is substantially larger as a business segment than our total med-surg businesses in the United States.

Interesting. Then one other kind of big picture follow-up for you, John.

And just congrats on a really strong year. Kind of the big picture question I have is really on the revenue growth guidance in the LRP.

Obviously, you sound really bullish on opportunities internationally and opportunities with new products. And at the LRP growth rate is little bit below the growth that you’re putting up today.

Is that just a function of an exceptional year this year? Or are there other headwinds worth calling out in the LRP?

Yeah. Great question, Bob.

I guess, if I would reflect a little bit on the first 6 quarters of being at Hill-Rom, I joined when we were growing at 2%, and it’s now exiting last year at 8%, so pretty nice acceleration, and on a full year basis, going from 3% in 2019 to over 6%, actually 7% this year, so again, nice core revenue acceleration over the year. As we look forward, especially on a 3-year plan perspective, I think, we’re – we’d be well advised to be prudent and balanced and looking at all the puts and takes, and things that can happen over a 3-year period.

So you’ll – I think, you’ll see that reflected in our long-range guidance – long-range outlook of 5% top-line core growth.In the near-term, we do feel very bullish and confident about our outlook to drive this growth. However, we had a really strong Centrella performance in 2019.

It’s probably wise, again, to not think we can sustain that kind of high level double-digit growth rates that we saw in the med-surg category into 2020. So we’ve adjusted our expectations there, as we think about our guidance, and that’s really the primary driver.

And as new products launch – they’re continuing to ramp nicely the products that we’ve launched. And we expect to see the new products launching in 2020 to be starting to perform and contribute, the 6 products I mentioned that we’re going to launch in 2020.So from a headwind point of view, we don’t see it, it’s all factored in, and really thought about having a very balanced perspective on both the next year as well as the next 3 years.

Great. Okay.

That makes sense. Thanks very much.

Thank you.

Rick Wise of Hill-Rom?

Good morning, everybody. Hi.

Welcome to the team.

In terms of the balance sheet, I mean you’ve done an excellent job of delevering the balance sheet, generating free cash, debt now at 3.2 times. And you’re projecting over $1 billion – could be, seems to me, well over $1 billion in free cash flow over the 3-year period.

A couple of questions related to that. If debt pay down remains your near-term priority, pending M&A, where would you like to see it sort of stabilize?

And maybe just roll this into a discussion about and as we’re thinking about M&A, is the pipeline filled? Do you have any particular priorities there, John?

Does it – are you more inclined, as you look at the 3 businesses to focus on adding to one more than another? Or no, it’s more opportunistic?

Yeah. Thanks, Rick from Stifel, not Hill-Rom.

But listen, I think, I mean – let me – I’ll turn the part of the question over to Barb around leverage. But in terms of strategic priorities of our capital, first and foremost, is M&A.

We do see, continue to see, really nice opportunities to build out our category leadership strategy in all 3 businesses. We have a very active process around reviewing our pipeline of opportunities.

We’re engaged on multiple fronts, our team there, as you know, has been significantly enhanced and expanded. And it’s giving us the visibility into a lot more opportunities than we did even 12 months ago.So I like our optionality and our opportunities there.

And I wouldn’t necessarily say we’re biasing one over the other. There – I love all 3 of our businesses and it’s going to be really depending on what kind of opportunities we see in front of us and which ones we’re able to pursue.

As you mentioned, I think, we have the financial flexibility to do – need to do a number of these per year going forward. And the structure of the company and its decentralized approach allows us to work on multiple fronts in parallel, while we do this.So I’ll hand it over to Barb for the leverage question.

And thanks for the question on leverage. You’re right, we’re at 3.2 currently, which is also where we started the year.

So we’ve maintained 3.2, while doing 2 acquisitions and returning nearly $180 million back to shareholders throughout the course of the year, which I think it’s a testament to our strong cash flow generation. When we think about target range, I think, that we would – again, our priority is to fuel M&A.

And as John just outlined, we think that we have a really good opportunities in front of us. Absent good opportunities, we could see – seeing our target leverage going down to somewhere in the 2.5 range, but we don’t see that as a probability in the near-term just because we see lots of opportunities out there for us to invest and really drive continued top-line growth.

Great. And just 2 last for me.

Just quickly on PSS, your slides emphasize that you’re benefiting from solid orders and backlog. Is the right way to read that, that the business, even with the tough comp, is in pretty stable shape on the bed front and you’re feeling pretty good?

Is that the right takeaway heading into this current fiscal year or the new fiscal year? And just last, John, if I could, we’ve talked about some of the potential challenges and headwinds, but if there were upside, particularly on the sales side looking at the next 2 years?

Is it – do you think it would come from – is it better execution? Is it from the new products?

Is it from faster OUS emerging market penetration or et cetera, et cetera? Or no, it’s all of the above?

Thank you so much.

Yeah. Okay.

Good question. And I think first of all in the PSS business, we’re really comfortable and confident with our overall portfolio there.

It’s a very balanced portfolio. I know, in the last year, we’ve talked a lot about med-surg and Centrella.

But it’s a large business, it’s very balanced, it’s got multiple areas of growth that are – have been delivering very consistently over the last 6 quarters I’ve been here. In terms of where the future upside or growth is coming from, where we could see that that kind of performance.

I think the investments we’re making in new products, acquisitions and emerging markets are all key focus areas for us. We’re very, very intentional about where we’re investing and how we’re tracking and how we’re measuring ourselves there.So again, it comes back to our ability to execute, our team is very motivated, highly engaged, they’re doing a great job.

And I think they continue to perform the way they’re doing and we’ll be pleased with the outcome versus our guidance.

Thank you so much.

Great. Thanks, John.

You have some very strong assumptions for international in your plan. I just want to get a sense of like you said you were kind of reinvigorating it.

What went wrong over the last couple of years and kind of how are you fixing it?

Yeah. I guess, I would start with the premise that they’re ambitious plans.

I would say they’re balanced and appropriately cautious. Our fiscal 2020 guidance has baked into it low-single-digit growth in the established markets and then exiting with double-digit growth as we get to the back half of the year.

So in total for the year, it’s high-single-digit growth in emerging markets. We’re exiting at that level in the emerging markets, so I don’t think it’s built with any kind of significant risk as we look at fiscal 2020.

And when rolling forward in the 3-year outlook, again, I don’t think it’s an overly ambitious set of expectations.Now that said, I’d love seeing results for a few more quarters before raising expectations on an area that we’ve had some chronic up and down performance around. So let’s take it a quarter at a time, see how things progress and we’ll take it from there.

But as it is quantified and rolled into our guidance, I feel really good about it.

Okay, great. And then, sorry for you asking this question.

But I believe a lot of your people have been brought over from Baxter over the last couple of years. Have you taken an enhanced look at certain accounting practices that are affecting them?

And how confident are you that those issues haven’t also been adopted at Hill-Rom?

So I guess I’ll take that question.

You, are you from Baxter?

First of all, I’m not from Baxter. And I’m not aware of anybody on my direct leadership team that came over from Baxter either.

So as we think about our accounting practices, and our books and records, we’re really confident in what we’re doing and how we’re doing it.

Thank you very much, Barb.

Great, Jack. We have time for two more questions, Jack.

Yeah. Thanks.

Just wanted to start with, I guess, Breathe Technologies. So I think the non-invasive ventilation category is part of the round 2021 of competitive bidding.

So does that affect the Breathe products? And can you just comment on whether or not that you bid there and what you kind of expect to happen with reimbursement, how that will affect that business?

Yeah. So we’re participating in competitive bidding for that product category.

It is partly competitive bidding process. We knew that going into the acquisition.

It doesn’t take effect until 2021. There is no impact whatsoever for fiscal 2020.And we feel good about where we stand and what our opportunities are in the competitive bidding front.

The NIV market, again, as I mentioned, especially NIV in the home, which is where we’re focused more than the – probably little more than the acute care categories, is a high-growing double-digit market for us for the overall and we’re going to be entering that space from a low market share position.

Okay. That’s helpful.

And then, just on the smart bed features like EarlySense and WatchCare, can you give us an update, are there any kind of metrics there you can give us in terms of adoption and impact on growth in the PSS business?

Yeah, I think it’s – first of all, I think it’s a really important differentiator to our overall product offering, the smart bed and through to the smartphone and the whole ecosystem and connectivity and future-proofing investments that customers are making.In terms of its revenue contribution in fiscal 2019 and it hasn’t been really that material, both of those products. But we do expect them to ramp as we enter 2020 and start seeing a dedicated sales team focused on that with some dedicated specialist.I will tell you then, in areas where we have turned on and activated the EarlySense device on our products, we’ve gotten back some incredible stories of patients that we’re rescuing and detecting changes in heart rate, respiratory rate, over time as the continuous sensors is deployed and activated.So bringing that type of alert and alarm on to the nurse call system and not just at the bedside, and then in the future on to the Voalte platform is really going to be a very compelling value proposition and game-changer in the marketplace for really helping rescue patients that are in deterioration.

And also as we think about our digital product offerings that we’ll be rolling out later in fiscal 2020 that will be directed at patient deterioration and falls, that same kind of connectivity and notification systems will be deployed on the care communications platform.

Great. Thanks a lot.

Hey, good morning, everybody. I have a quick, I guess, clarification one for, Barb, and then a big picture one.

The onetime issue in gross margins, can you just clarify what that was and is it something that could, I guess, occur again?

Hi, Kristen, it’s Barb. Thanks for the question.

They really were onetime items. We had some discontinued projects during the quarter as well as some small inventory adjustments that were really one-offs in the quarter.

They amounted to about $4 million in total, but not something that we would expect to be a recurring thing. That’s why we called them out.

Okay, great. And then, I guess, just kind of big picture, I guess, kind of going back to, I think it was a question on the 5% LRP.

I guess, I’m just having a little difficult time and maybe, I guess, it’s a little bit of conservatism as you were saying, John.As I think through just some of your numbers that you have in here just with respect to the new products going to $750 million, and that’s contributing 200 basis points annually. And then emerging markets contributing 100 basis points and just Voalte is being accretive to growth and the opportunities with Breathe, you’ve done a lot from a portfolio management and the acquisition seemed pretty positive, doing a lot on the new product front.You got all these things moving very favorably.

I’m just kind of surprised that 5% is the number. And thinking ahead too, to the extent that you guys are doing more things on the M&A side, I know you said that those are likely to be additive.

But I want to just make sure that those are really additive to the LRP, because it seems like you’ve been doing a lot. But it seems like a lot of running and standing kind of still, I guess, on the 5% growth.

So just kind of walk me through, I guess, how I should really think about the growth prospects for the company?

Yeah, thanks. Great question, Kristen, and something obviously we spend a great deal of time around.

We feel really good about where we are. So let me start with that, really good, and tremendous amount of confidence and conviction on the go-forward outlook and our ability to execute against that outlook.That said, we – just to confirm, any additional M&A will be on top of what we’ve outlined today.

It’s not going to get somehow rolled into our guidance and our outlook here. And then, secondly, I think until – the one part of the weighted average market growth rate, if you will, that’s kind of holding us back a little bit is our more established markets internationally.And we’ve got a little bit of work to do there.

Once we can get those performing closer to the company average, in mid-single-digits, I think there is room for increased bullishness on the outlook. But until that time, I think there are a lot of things that can happen over a 3-year period and we’re going to be prudent and balanced.